Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.

Abstract:

:In a pilot study to reduce the duration of treatment and potential long-term toxicities, 39 patients with acute promyelocytic leukemia in remission received a single cycle of intensive consolidation therapy, followed by intermittent ATRA maintenance. Consolidation therapy required prolonged hospitalization and was associated with a high incidence of mucositis (43% grade II or greater) and documented infection (45%). No deaths occurred during consolidation. Seven patients have relapsed; all other patients are in molecular remission (median follow-up, 2.75 years). Kaplan-Meier estimate of 3 year disease-free survival is 73% (95% confidence interval 55-91%). The relapse rate (0.06 relapses/patient-year of follow-up) is well within the range of larger published series that administer more prolonged consolidation. One patient has developed secondary myelodysplastic syndrome. These pilot data suggest that decreasing the total duration of consolidation chemotherapy did not compromise disease-free survival for APL patients induced with ATRA/anthracycline and given intermittent ATRA maintenance. However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL.

journal_name

Am J Hematol

authors

Gore SD,Smith BD,Gojo I,Grever M,Kaufmann SH,Letendre L,Leonard DG,Marcucci G,Miller CB,Morris L,Piantadosi S,Prior T,Stock W,Karp JE

doi

10.1002/ajh.20354

keywords:

subject

Has Abstract

pub_date

2005-06-01 00:00:00

pages

119-27

issue

2

eissn

0361-8609

issn

1096-8652

journal_volume

79

pub_type

杂志文章
  • A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.

    abstract::Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compared two salvage regimens; mitoxantrone, etoposide, and cytarabine (MEC)...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ajh.25838

    authors: Christian S,Arain S,Patel P,Khan I,Calip GS,Agrawal V,Sweiss K,Griffin S,Cahill K,Konig H,Esen A,Shergill A,Odenike O,Stock W,Quigley JG

    更新日期:2020-08-01 00:00:00

  • Diagnosis and current treatments for primary iron overload.

    abstract::Primary iron overload encompasses a variety of genetic iron overload syndromes, dominated in frequency by HFE-related, or Type 1 hemochromatosis, for which French diagnostic and therapeutic guidelines have been recently proposed. Differential diagnosis of Type 1 hemochromatosis can be made from both clinical data and ...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.21071

    authors: Brissot P

    更新日期:2007-12-01 00:00:00

  • The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).

    abstract::This retrospective study included 246 patients with a new diagnosis of Hodgkin Lymphoma (HL) with a localized-stage (IA-IIA), consecutively admitted from January 2002 to December 2008, by twelve Italian hematological centers on behalf of Fondazione Italiana Linfomi (FIL). Patients were staged at baseline and after two...

    journal_title:American journal of hematology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/ajh.23994

    authors: Rigacci L,Puccini B,Zinzani PL,Biggi A,Castagnoli A,Merli F,Balzarotti M,Stelitano C,Spina M,Vitolo U,Stefoni V,Levis A,Gotti M,Rosaria S,Maria SP,Bosi A,Gallamini A

    更新日期:2015-06-01 00:00:00

  • Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.

    abstract::Although treatment with plasma exchange increased the survival of patients with thrombotic thrombocytopenia purpura to 80% in the 1980s, no further increase of survival occurred over the next 20 years. However, more consistent use of adjuvant treatment with corticosteroids and rituximab in recent years has begun to fu...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.23126

    authors: George JN

    更新日期:2012-05-01 00:00:00

  • Molecular basis and hematological characterization of Hb H disease in southeast Asia.

    abstract::We molecularly characterized sixty-seven cases of Hb H disease by the polymerase chain reaction. The strategy depends on amplifying the alpha-thalassemia-1 (alpha-thal-1) gene by primers flanking the breakpoint and sequence differences of the 3' end of the alpha-globin gene and the nonhomologous elements I, II, and II...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830450405

    authors: Liu TC,Chiou SS,Lin SF,Chen TP,Tseng WP,Chen PH,Chang JG

    更新日期:1994-04-01 00:00:00

  • First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.

    abstract::Imatinib mesylate radically changed the natural history of chronic myeloid leukemia (CML). The recent availability of alternative tyrosine kinase inhibitors (TKIs) renders the clinical management of CML more complex. In this article, we summarize our long-term single institution experience. From 2003 to 2012, 102 pati...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/ajh.23804

    authors: Viganò I,Di Giacomo N,Bozzani S,Antolini L,Piazza R,Gambacorti Passerini C

    更新日期:2014-10-01 00:00:00

  • Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

    abstract::This analysis, using data from the bortezomib-melphalan-prednisone (VMP) arm of the Phase III VISTA study, investigated whether increased cumulative bortezomib dose could improve overall survival (OS) in transplant-ineligible patients with previously untreated multiple myeloma. Median cumulative bortezomib dose receiv...

    journal_title:American journal of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ajh.23933

    authors: Mateos MV,Richardson PG,Dimopoulos MA,Palumbo A,Anderson KC,Shi H,Elliott J,Dow E,van de Velde H,Niculescu L,San Miguel JF

    更新日期:2015-04-01 00:00:00

  • Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.

    abstract::The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)-associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers and networks for adult immune cytopenias and SLE involved patients ≥18 years old...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ajh.24999

    authors: Serris A,Amoura Z,Canouï-Poitrine F,Terrier B,Hachulla E,Costedoat-Chalumeau N,Papo T,Lambotte O,Saadoun D,Hié M,Blanche P,Lioger B,Gottenberg JE,Godeau B,Michel M

    更新日期:2018-03-01 00:00:00

  • Clonal hematopoiesis in patients with dyskeratosis congenita.

    abstract::Dyskeratosis congenita (DC) is a rare inherited telomeropathy most frequently caused by mutations in a number of genes all thought to be involved in telomere maintenance. The main causes of mortality in DC are bone marrow failure as well as malignancies including leukemias and solid tumors. The clinical picture includ...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ajh.24552

    authors: Perdigones N,Perin JC,Schiano I,Nicholas P,Biegel JA,Mason PJ,Babushok DV,Bessler M

    更新日期:2016-12-01 00:00:00

  • Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.

    abstract::Thalidomide is being increasingly used in hematology and oncology. Its use is associated with neuropathy, sedation, edema, fatigue, constipation, and deep venous thrombosis. Cytopenias are unusual, but there are case reports. However, there are no reports of isolated thrombocytopenia. We describe here a case of prolon...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.20949

    authors: Prasad HK,Kaushal V,Mehta P

    更新日期:2007-09-01 00:00:00

  • Studies of the effects of trimethoprim and sulfamethoxazole on human granulopoiesis.

    abstract::Trimethoprim and sulfamethoxazole (Bactrim r) is a widely used antibiotic combination effective against a broad spectrum of microbial organisms. There are reports of neutropenia developing during even brief periods of oral therapy, particularly in individuals with either folate deficiency or increased folate requireme...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830230102

    authors: Bjornson BH,McIntyre AP,Harvey JM,Tauber AI

    更新日期:1986-09-01 00:00:00

  • Chronic lymphoproliferative disorder with regulatory T-cell phenotype.

    abstract::We report a case of T-cell chronic lymphoproliferative disorder (CLPD) that shows neither features of T-cell prolymphocytic leukemia nor disease progression for more than 34 months. Flow cytometric analyses of the lymphocytes revealed high expression of CD4 and CD25. Up-regulation of Foxp3, a master regulatory gene fo...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.20688

    authors: Kikuchi T,Katayama Y,Kubonishi S,Watanabe T,Watanabe Y,Matsuoka K,Maeda Y,Namba N,Masunari T,Nasu R,Ikeda K,Tanimoto M

    更新日期:2006-09-01 00:00:00

  • Community experience with bortezomib in patients with multiple myeloma.

    abstract::Community practice experience allows a nonselective care of patient using information derived from a more controlled clinical trial environment. We present our community experience with multiple myeloma patients with advanced age, long disease duration since diagnosis, advanced stage, multiple prior therapies includin...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.20883

    authors: Onitilo AA,Engel J,Olatosi B,Fagbemi S

    更新日期:2007-07-01 00:00:00

  • Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.

    abstract::A small number of thromboembolic events, including deep venous thrombosis and myocardial infarction, have been reported in patients receiving IVIG. These events have primarily occurred in patients receiving high-dose IVIG and have been attributed to an increase in blood viscosity. To test the hypothesis that a procoag...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/1096-8652(200009)65:1<30::aid-ajh5>3.0.co;

    authors: Wolberg AS,Kon RH,Monroe DM,Hoffman M

    更新日期:2000-09-01 00:00:00

  • Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.

    abstract::Several studies reported improved outcomes of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with pediatric-based ALL regimens. This prompted the prospective investigation of a pediatric Augmented Berlin-Frankfurt-Münster (ABFM) regimen, and its comparison with hyper-fractionated cy...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.24419

    authors: Rytting ME,Jabbour EJ,Jorgensen JL,Ravandi F,Franklin AR,Kadia TM,Pemmaraju N,Daver NG,Ferrajoli A,Garcia-Manero G,Konopleva MY,Borthakur G,Garris R,Wang S,Pierce S,Schroeder K,Kornblau SM,Thomas DA,Cortes JE,O'Brie

    更新日期:2016-08-01 00:00:00

  • Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States.

    abstract::Non-Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post-transplantation non-Hodgkin lymphoma, but few studies of transplant recipients have examined subtype-s...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.23726

    authors: Gibson TM,Engels EA,Clarke CA,Lynch CF,Weisenburger DD,Morton LM

    更新日期:2014-07-01 00:00:00

  • Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.

    abstract::The effect of several iron chelators on iron uptake and release by mouse peritoneal macrophages has been investigated. The 1,2-dimethyl (L1) and 1-ethyl-2-methyl (L1NEt) derivatives of 3-hydroxypyrid-4-one markedly enhanced iron mobilisation from macrophages pulsed with 59Fe-transferrin-antitransferrin immune complexe...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830340106

    authors: Brock JH,Licéaga J,Arthur HM,Kontoghiorghes GJ

    更新日期:1990-05-01 00:00:00

  • A new density gradient system for the separation of human red blood cells.

    abstract::A new density system for the separation of human red blood cells by density-gradient centrifugation is described. The gradient medium is made with colloidal silica particles coated with polyvinylpyrrolidone suspended in aqueous solution of meglamine diatrizoate. By this method, more than 10 red-cell fractions can be s...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830080307

    authors: Vettore L,De Matteis MC,Zampini P

    更新日期:1980-01-01 00:00:00

  • Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.

    abstract::The incidence of drug-induced neutropenia has not changed in the western hemisphere over the last 30 years. Yet, the drug panorama has changed considerably. This implies that host factors may play an intriguing role for this idiosyncratic reaction. The knowledge as to mechanisms for the reaction has advanced with emer...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.21433

    authors: Tesfa D,Keisu M,Palmblad J

    更新日期:2009-07-01 00:00:00

  • Sickle cell anemia as a syndrome: a review of diagnostic features.

    abstract::Sickle cell (SS) disease is a complex of various genetic conditions. In some, homozygosity for the beta S gene may be present alone or in combination with the heterozygous or homozygous alpha-thalassemia-2 condition. Such combinations might ameliorate the clinical and hematological condition of the patient. The same m...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.2830060210

    authors: Huisman TH

    更新日期:1979-01-01 00:00:00

  • Factor VIII and IX gene polymorphisms and carrier analysis in Indian population.

    abstract::The efficacy of the three common intra- and extragenic polymorphic sites of the factor VIII and IX genes has been examined in the Indian population, with an aim to develop a strategy that would be accurate and informative, yet economical. The approach for hemophilia A carrier detection includes tests for BclI, XbaI, a...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(199704)54:4<271::aid-ajh2>

    authors: Shetty S,Ghosh K,Pathare A,Colah R,Badakare S,Mohanty D

    更新日期:1997-04-01 00:00:00

  • High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma.

    abstract::Cutaneous lymphoma is a disease characterized with massive skin infiltration of lymphoid malignant cells. They commonly express some T-cell markers, such as CD2, CD3, CD4, and CD7, and thus termed as CTCL (cutaneous T cell lymphoma). Here, we present a case with CD56/N-CAM-positive cutaneous lymphoma, which appears ly...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830470406

    authors: Adachi M,Maeda K,Takekawa M,Hinoda Y,Imai K,Sugiyama S,Yachi A

    更新日期:1994-12-01 00:00:00

  • Relative iron deficiency in hereditary spherocytosis.

    abstract::Seventy-three patients with hereditary spherocytosis (HS) (58 nonsplenectomized, 15 splenectomized) were studied to evaluate iron status and the adequacy of iron availability for erythropoiesis. Splenectomized patients, who had hemoglobin levels in the normal or upper normal range, had higher levels of serum iron, tra...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830310202

    authors: Zanella A,Barosi G,Berzuini A,Colombo MB,Quaglini S,Volpes D,Sirchia G

    更新日期:1989-06-01 00:00:00

  • Lack of evidence of circulating retroviral antibodies in patients with classic Hodgkin's disease.

    abstract::Because of the T-cell abnormalities observed in Hodgkin's disease and the growing number of Hodgkin's disease cases observed in association with the acquired immunodeficiency syndrome (AIDS), concern has been expressed that a retrovirus may be the primary cause of Hodgkin's disease. We examined plasma specimens from 1...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830270104

    authors: Chorba TL,Kalyanaraman VS,Lacher MJ,Schulof RS

    更新日期:1988-01-01 00:00:00

  • Chylothorax in chronic lymphocytic leukemia patient.

    abstract::Chronic lymphocytic leukemia (CLL) is rarely complicated by chylothorax: we present a 93-year-old woman with CLL who developed recurrent pleural effusions that were ultimately found to be chylous in nature. Despite eight repeated thoracenteses, she continued to experience re-accumulation of fluid, and therefore, video...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.10142

    authors: Doerr CH,Staats BA,Markovic SN

    更新日期:2002-07-01 00:00:00

  • Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

    abstract::Acute myeloid leukemia (AML) is defined as ≥20% myeloblasts, representing a change from original guidelines where ≤30% blasts were considered as myelodysplastic syndromes (MDS), and 20-29% blasts classified as refractory anemia with excess blasts in transformation (RAEB-T). Whether the diagnostic bone marrow blast per...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.24252

    authors: DiNardo CD,Garcia-Manero G,Pierce S,Nazha A,Bueso-Ramos C,Jabbour E,Ravandi F,Cortes J,Kantarjian H

    更新日期:2016-02-01 00:00:00

  • Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene.

    abstract::We analyzed 12 MLL/ENL positive ALL patients consecutively diagnosed between 1999 and 2009. The MLL/ENL fusion was identified in 4/150 (2.6%), 8/993 (0.8%), and 0/70 of pediatric, adult, and elderly patients, respectively. Eight patients had a WBC count >50 × 10(9) /L. Ten cases had an evaluable immunophenotyping. A B...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.22161

    authors: Elia L,Grammatico S,Paoloni F,Vignetti M,Rago A,Cenfra N,Mecarocci S,Mancini M,Luciani M,Di Raimondo F,Cazzaniga G,Matarazzo M,Moleti ML,Santoro L,Gaidano G,Foà R,Mandelli F,Cimino G

    更新日期:2011-12-01 00:00:00

  • Abnormal gamma IFN and alpha TNF secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura (ATP) patients: their implication in the clinical course of the disease.

    abstract::Gamma inferferon (gamma IFN), alpha tumor necrosis factor (alpha TNF), and interleukin 6 (IL-60) are cytokines produced by a wide variety of cells, including T lymphocytes and NK cells. These cytokines affect B-cell proliferation and differentiation into immunoglobulin secreting cells. In addition, gamma IFN and alpha...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830490403

    authors: Garcia-Suarez J,Prieto A,Reyes E,Manzano L,Arribalzaga K,Alvarez-Mon M

    更新日期:1995-08-01 00:00:00

  • Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.

    abstract::Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long-term disease-specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty-eight of 40 patients (aged 9-71 years) clinically stable on ERT with imiglucerase, safely switched to a compa...

    journal_title:American journal of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1002/ajh.24007

    authors: Elstein D,Mehta A,Hughes DA,Giraldo P,Charrow J,Smith L,Shankar SP,Hangartner TN,Kunes Y,Wang N,Crombez E,Zimran A

    更新日期:2015-07-01 00:00:00

  • Treatment of individuals who cannot receive blood products for religious or other reasons.

    abstract::By virtue of their religious principles, Jehovah's Witnesses (JWs) generally object to receiving blood products, raising numerous ethical, legal, and medical challenges for providers who care for these patients, especially in the emergent setting. In this review, we discuss several areas relevant to the care of JWs, i...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.24889

    authors: Scharman CD,Burger D,Shatzel JJ,Kim E,DeLoughery TG

    更新日期:2017-12-01 00:00:00